Literature DB >> 2030367

Intermittent long-term adrenocorticosteroid treatment of myasthenia gravis.

N Wakata1, Y Kawamura, M Kobayashi, Y Araki, M Kinoshita.   

Abstract

It is widely accepted that a long-term, alternate-day administration of adrenal corticosteroids after thymectomy is one of the most effective treatments of myasthenia gravis. However, some patients with myasthenia gravis show a tendency to develop steroid dependency, and require extremely prolonged administration of fairly high doses of steroids. Various types of adverse reactions to steroids are likely to occur in such cases. To avoid this, intermittent, single-dose administration of steroids was performed on a trial basis in the present study. Prednisolone, in doses of 50-100 mg, was given once every 3-7 days in three steroid-dependent myasthenic patients, in one case for up to 6 years. The effects of the intermittent treatment were as good as, and adverse effects less frequently found than in single-dose, alternate-day administration.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2030367     DOI: 10.1007/bf00319703

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  6 in total

1.  Glucocorticoid therapy.

Authors:  L Axelrod
Journal:  Medicine (Baltimore)       Date:  1976-01       Impact factor: 1.889

2.  Benefit from alternate-day prednisone in myasthenia gravis.

Authors:  J R Warmolts; W K Engel
Journal:  N Engl J Med       Date:  1972-01-06       Impact factor: 91.245

3.  The rationale of alternate-day corticosteroid therapy.

Authors:  M E Jacobson
Journal:  Postgrad Med       Date:  1971-02       Impact factor: 3.840

4.  Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment.

Authors:  M E Seybold; D B Drachman
Journal:  N Engl J Med       Date:  1974-01-10       Impact factor: 91.245

5.  Alternate-dy prednisone in a patient with myasthenia gravis.

Authors:  J R Warmolts; W K Engel; J N Whitaker
Journal:  Lancet       Date:  1970-12-05       Impact factor: 79.321

6.  Treatment of myasthenia gravis. Report on 139 patients.

Authors:  C Scoppetta; P Tonali; A Evoli; P David; F Crucitti; M L Vaccario
Journal:  J Neurol       Date:  1979       Impact factor: 4.849

  6 in total
  1 in total

1.  Steroid therapy without primary dose escalation for postthymectomy crisis in 2 thymomatous myasthenia gravis patients.

Authors:  Masayoshi Inoue; Kentaro Kimura; Katsuko Hasegawa; Kiyohiro Fujiwara; Katsuhiro Nakagawa; Tsutomu Yasumitsu
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2002-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.